Iradimed Corp (IRMD)

$53.23

Market is closed - opens 8 PM, 25 Nov 2024

Performance

  • $52.37
    $53.81
    $53.23
    downward going graph

    1.62%

    Downside

    Day's Volatility :2.68%

    Upside

    1.08%

    downward going graph
  • $40.05
    $57.95
    $53.23
    downward going graph

    24.76%

    Downside

    52 Weeks Volatility :30.89%

    Upside

    8.14%

    downward going graph

Returns

PeriodIradimed CorpSector (Health Care)Index (Russel 2000)
3 Months
16.12%
-7.3%
0.0%
6 Months
26.08%
-0.5%
0.0%
1 Year
23.62%
10.5%
0.0%
3 Years
34.15%
8.8%
-24.0%

Highlights

Market Capitalization
674.6M
Book Value
$6.59
Dividend Share
0.45
Dividend Yield
1.13%
Earnings Per Share (EPS)
1.46
PE Ratio
36.46
PEG Ratio
4.46
Wall Street Target Price
60.0
Profit Margin
26.12%
Operating Margin TTM
31.59%
Return On Assets TTM
14.67%
Return On Equity TTM
23.58%
Revenue TTM
71.3M
Revenue Per Share TTM
5.64
Quarterly Revenue Growth YOY
11.0%
Gross Profit TTM
41.3M
EBITDA
22.2M
Diluted Eps TTM
1.46
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
1.66
EPS Estimate Next Year
1.75
EPS Estimate Current Quarter
0.38
EPS Estimate Next Quarter
0.39

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Iradimed Corp(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 12.72%

Current $53.23
Target $60.00

Company Financials

FY18Y/Y Change
Revenue
30.4M
↑ 31.88%
Net Income
6.3M
↑ 1161.29%
Net Profit Margin
20.71%
↑ 18.54%
FY19Y/Y Change
Revenue
38.5M
↑ 26.54%
Net Income
9.6M
↑ 52.79%
Net Profit Margin
25.0%
↑ 4.29%
FY20Y/Y Change
Revenue
31.7M
↓ 17.65%
Net Income
1.4M
↓ 85.79%
Net Profit Margin
4.32%
↓ 20.68%
FY21Y/Y Change
Revenue
41.8M
↑ 31.83%
Net Income
9.3M
↑ 581.19%
Net Profit Margin
22.3%
↑ 17.98%
FY22Y/Y Change
Revenue
53.3M
↑ 27.48%
Net Income
12.8M
↑ 37.55%
Net Profit Margin
24.06%
↑ 1.76%
FY23Y/Y Change
Revenue
65.6M
↑ 23.0%
Net Income
17.2M
↑ 34.03%
Net Profit Margin
26.22%
↑ 2.16%
Q2 FY23Q/Q Change
Revenue
16.1M
↑ 4.23%
Net Income
4.2M
↑ 22.72%
Net Profit Margin
25.91%
↑ 3.9%
Q3 FY23Q/Q Change
Revenue
16.5M
↑ 2.32%
Net Income
5.1M
↑ 21.23%
Net Profit Margin
30.7%
↑ 4.79%
Q4 FY23Q/Q Change
Revenue
17.5M
↑ 5.74%
Net Income
4.5M
↓ 10.41%
Net Profit Margin
26.01%
↓ 4.69%
Q1 FY24Q/Q Change
Revenue
17.6M
↑ 0.84%
Net Income
4.1M
↓ 8.88%
Net Profit Margin
23.51%
↓ 2.5%
Q2 FY24Q/Q Change
Revenue
17.9M
↑ 1.88%
Net Income
4.9M
↑ 18.49%
Net Profit Margin
27.34%
↑ 3.83%
Q3 FY24Q/Q Change
Revenue
18.3M
↑ 2.21%
Net Income
5.0M
↑ 3.03%
Net Profit Margin
27.55%
↑ 0.21%
FY18Y/Y Change
Total Assets
48.4M
↑ 24.17%
Total Liabilities
6.5M
↑ 6.82%
FY19Y/Y Change
Total Assets
66.7M
↑ 37.75%
Total Liabilities
11.2M
↑ 72.47%
FY20Y/Y Change
Total Assets
71.1M
↑ 6.5%
Total Liabilities
9.7M
↓ 13.59%
FY21Y/Y Change
Total Assets
82.9M
↑ 16.62%
Total Liabilities
10.7M
↑ 10.59%
FY22Y/Y Change
Total Assets
85.5M
↑ 3.17%
Total Liabilities
11.8M
↑ 10.58%
FY23Y/Y Change
Total Assets
92.2M
↑ 7.77%
Total Liabilities
20.7M
↑ 75.12%
Q2 FY23Q/Q Change
Total Assets
81.4M
↑ 7.68%
Total Liabilities
12.4M
↑ 10.22%
Q3 FY23Q/Q Change
Total Assets
87.4M
↑ 7.34%
Total Liabilities
12.8M
↑ 3.26%
Q4 FY23Q/Q Change
Total Assets
92.2M
↑ 5.43%
Total Liabilities
20.7M
↑ 61.52%
Q1 FY24Q/Q Change
Total Assets
88.0M
↓ 4.49%
Total Liabilities
11.9M
↓ 42.65%
Q2 FY24Q/Q Change
Total Assets
89.9M
↑ 2.2%
Total Liabilities
10.3M
↓ 13.58%
Q3 FY24Q/Q Change
Total Assets
94.2M
↑ 4.78%
Total Liabilities
10.8M
↑ 5.22%
FY18Y/Y Change
Operating Cash Flow
7.4M
↑ 115.93%
Investing Cash Flow
1.5M
↓ 248.1%
Financing Cash Flow
929.9K
↓ 148.93%
FY19Y/Y Change
Operating Cash Flow
10.2M
↑ 38.73%
Investing Cash Flow
3.2M
↑ 111.18%
Financing Cash Flow
2.0M
↑ 117.25%
FY20Y/Y Change
Operating Cash Flow
5.8M
↓ 43.15%
Investing Cash Flow
247.0K
↓ 92.29%
Financing Cash Flow
522.5K
↓ 74.14%
FY21Y/Y Change
Operating Cash Flow
11.3M
↑ 93.52%
Investing Cash Flow
648.2K
↑ 162.48%
Financing Cash Flow
24.4K
↓ 95.33%
FY22Y/Y Change
Operating Cash Flow
10.0M
↓ 10.8%
Investing Cash Flow
-1.4M
↓ 312.11%
Financing Cash Flow
-12.7M
↓ 52122.11%
Q2 FY23Q/Q Change
Operating Cash Flow
3.5M
↓ 24.37%
Investing Cash Flow
-378.3K
↓ 94.23%
Financing Cash Flow
-89.8K
↓ 99.32%

Technicals Summary

Sell

Neutral

Buy

Iradimed Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Iradimed Corp
Iradimed Corp
5.43%
26.08%
23.62%
34.15%
131.84%
Stryker Corporation
Stryker Corporation
5.95%
16.58%
31.06%
51.19%
89.49%
Boston Scientific Corp.
Boston Scientific Corp.
2.92%
21.0%
61.78%
123.71%
110.04%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-0.18%
-19.41%
3.8%
-37.42%
-13.61%
Abbott Laboratories
Abbott Laboratories
0.64%
12.98%
14.47%
-5.4%
39.38%
Medtronic Plc
Medtronic Plc
-6.57%
5.94%
9.17%
-23.96%
-22.88%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Iradimed Corp
Iradimed Corp
36.46
36.46
4.46
1.66
0.24
0.15
0.01
6.59
Stryker Corporation
Stryker Corporation
41.86
41.86
2.69
12.05
0.19
0.07
0.01
52.86
Boston Scientific Corp.
Boston Scientific Corp.
75.62
75.62
1.63
2.46
0.09
0.05
NA
14.05
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
27.21
27.21
6.46
2.53
0.19
0.11
NA
16.18
Abbott Laboratories
Abbott Laboratories
35.64
35.64
2.25
4.68
0.15
0.06
0.02
22.94
Medtronic Plc
Medtronic Plc
29.55
29.55
1.63
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Iradimed Corp
Iradimed Corp
Buy
$674.6M
131.84%
36.46
26.12%
Stryker Corporation
Stryker Corporation
Buy
$148.7B
89.49%
41.86
16.34%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$134.9B
110.04%
75.62
11.26%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$41.6B
-13.61%
27.21
65.86%
Abbott Laboratories
Abbott Laboratories
Buy
$203.4B
39.38%
35.64
13.99%
Medtronic Plc
Medtronic Plc
Buy
$110.3B
-22.88%
29.55
12.06%

Insights on Iradimed Corp

  • Increasing Revenue

    Revenue is up for the last 18 quarters, 6.79M → 18.32M (in $), with an average increase of 5.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 4.13M → 5.04M (in $), with an average increase of 9.3% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 62.4% return, outperforming this stock by 31.9%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 123.7% return, outperforming this stock by 89.6%

Institutional Holdings

  • Nine Ten Capital Management LLC

    7.15%

  • BlackRock Inc

    6.46%

  • Renaissance Technologies Corp

    4.26%

  • Vanguard Group Inc

    4.06%

  • Copeland Capital Management, LLC

    3.33%

  • Bares Capital Management Inc

    2.24%

Company Information

iradimed corporation develops, manufactures, markets, and distributes magnetic resonance imaging (mri) compatible medical devices, and related accessories and services in the united states and internationally. it offers mri compatible intravenous (iv) infusion pump system with associated disposable iv tubing sets; and mri compatible patient vital signs monitoring system. the company also provides iv poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and spo2 monitoring with sensors and accessories. it serves hospitals, acute care facilities, and outpatient imaging centers. the company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. iradimed corporation was incorporated in 1992 and is headquartered in winter springs, florida.

Organization
Iradimed Corp
Employees
148
CEO
Mr. Roger E. Susi
Industry
Health Technology

FAQs